Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.56 |
| ▸ | MITF | O75030 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6312189 | 0.90 | MITF (0.64) | MAPTMITFKMT2ASLC6A2SLC6A3 | |
| SCHEMBL2972277 | 0.85 | LMNA (0.57) | MAPTKMT2ASLC6A2SLC6A3TDP1 | |
| SCHEMBL20400703 | 0.84 | MAPT (0.53) | MAPTKMT2ASLC6A2SLC6A3TDP1 | |
| SCHEMBL11491980 | 0.84 | MAPT (0.62) | MAPTKMT2ASLC6A2SLC6A3TDP1 | |
| SCHEMBL20400967 | 0.84 | L3MBTL1 (0.59) | MAPTKMT2ASLC6A2SLC6A3TDP1 | |
| SCHEMBL7342938 | 0.83 | MYC (0.55) | MAPTKMT2ASLC6A2SLC6A3TDP1 | |
| SCHEMBL30892476 | 0.83 | MYC (0.55) | MAPTKMT2ASLC6A2SLC6A3TDP1 | |
| SCHEMBL8061795 | 0.83 | LMNA (0.57) | MAPTMITFKMT2ASLC6A2SLC6A3 | |
| SCHEMBL15610591 | 0.82 | RAB9A (0.61) | MAPTKMT2ALMNAALDH1A1RAB9A | |
| SCHEMBL2146139 | 0.82 | HTT (0.58) | MAPTKMT2ASLC6A2SLC6A3TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11299480-B2 | 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors | UNIVERSITY OF HAWAII (US) | 2022-04-12 | — | — | US | disclosed |
| CN-108431004-B | Heterocyclic compounds | 武田药品工业株式会社 | 2021-02-12 | — | — | CN | disclosed |
| US-10787462-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-09-29 | — | — | US | disclosed |
| EP-3366684-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-02 | — | — | EP | disclosed |
| CN-111356456-A | 2-arylsulfonamido-iV-arylacetamide derived Stat3 inhibitor | 夏威夷大学 | 2020-06-30 | — | — | CN | disclosed |
| US-20180319819-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-11-08 | — | — | US | disclosed |
| EP-3366684-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-08-29 | — | — | EP | disclosed |
| WO-2018136935-A1 | 2-ARYLSULFONAMIDO-N-ARYLACETAMIDE DERIVATIZED STAT3 INHIBITORS | UNIVERSITY OF HAWAII (US) | 2018-07-26 | — | — | WO | disclosed |
| US-20170119734-A1 | TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE | INFINITY PHARMACEUTICALS, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20170119734-A1 | TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE | INFINITY PHARMACEUTICALS, INC. | 2017-05-04 | — | — | US | disclosed |
| US-7329685-B2 | 1-Phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivatives and related compounds as factor Xa inhibitors for the treatment of acute vascular diseases | GLAXO GROUP LIMITED (GB) | 2008-02-12 | — | — | US | disclosed |
| US-7329685-B2 | 1-Phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivatives and related compounds as factor Xa inhibitors for the treatment of acute vascular diseases | GLAXO GROUP LIMITED (GB) | 2008-02-12 | — | — | US | disclosed |
| US-7329685-B2 | 1-Phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivatives and related compounds as factor Xa inhibitors for the treatment of acute vascular diseases | GLAXO GROUP LIMITED (GB) | 2008-02-12 | — | — | US | disclosed |
| US-20070203206-A1 | 2-Pyrrolidone Derivatives And Use Thereof As Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-08-30 | — | — | US | disclosed |
| US-20070203206-A1 | 2-Pyrrolidone Derivatives And Use Thereof As Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-08-30 | — | — | US | disclosed |
| US-20070203206-A1 | 2-Pyrrolidone Derivatives And Use Thereof As Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-08-30 | — | — | US | disclosed |
| EP-1635817-B1 | 1-PHENYL-2-OXO-3-SULFONYLAMINO-PYRROLIDINE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR XA INHIBITORS FOR THE TREATMENT OF ACUTE VASCULAR DISEASES | GLAXO GROUP LTD (GB) | 2006-11-22 | — | — | EP | disclosed |
| US-20060148879-A1 | 1-Phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivatives and related compounds as factor xa inhibitors for the treatment of acute vascular diseases | GLAXO GROUP LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| EP-1633347-A1 | 2-PYRROLIDONE DERIVATIVES AND USE THEREOF AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004110434-A1 | 2-PYRROLIDONE DERIVATIVES AND USE THEREOF AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787462-B2 | Heterocyclic compound | RIPK1, RIPK4, RIPK3 | MAPT 4346/4885MITF 3072/4885KMT2A 1993/4885 |
| US-11299480-B2 | 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors | STAT3, JAK2, STAT5A | MAPT 3464/4885MITF 1540/4885KMT2A 510/4885 |
| US-20070203206-A1 | 2-Pyrrolidone Derivatives And Use Thereof As Factor Xa Inhibitors | TFPI, F2, F12 | MAPT 4144/4885MITF 1761/4885KMT2A 3615/4885 |
| US-20180319819-A1 | HETEROCYCLIC COMPOUND | RIPK1, RIPK4, RIPK3 | MAPT 4346/4885MITF 3072/4885KMT2A 1993/4885 |
| US-20170119734-A1 | TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE | FASN, ACSL1, HSD17B12 | MAPT 3762/4885MITF 1849/4885KMT2A 3490/4885 |
| US-20060148879-A1 | 1-Phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivatives and related compounds as factor xa inhibitors for the treatment of acute vascular diseases | SERPINE1, PLAT, SERPINC1 | MAPT 4729/4885MITF 1514/4885KMT2A 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.